Understanding the disease ā Researching therapies
Research
The Epidermolysis Bullosa Research Institute (EB RI), a non-profit, translational research and development institute based in Salzburg, is dedicated to improving the lives of ābutterfly childrenā.
The EB RI team is committed to advancing innovative research aimed at developing life-enhancing therapies and diagnostic solutions for ābutterfly childrenā.
Research at the EB Research Institute ā Science for innovative EB therapies
Building on 20 years of experience in EB research and through close collaboration with international research partners, clinical networks and patient organisations, EB RI integrates basic research, preclinical development and clinical application into a seamless process.
EB is not simply a skin condition; it can cause a wide range of symptoms and associated complications. Severe forms of EB present patients with particular challenges, including chronic wounds and an increased risk of aggressive skin tumours. Research into the condition is therefore wide-ranging and aims to address these complex aspects of EB through scientific innovation.
Translational research approach
A central component of the research is the development and optimisation of therapeutic approaches that specifically target the molecular causes and consequences of EB. These include both gene therapy strategies to correct disease-causing mutations and the identification of active substances for the treatment of EB-associated tumours. In addition, the team is investigating the role of the immune system in the treatment of tumours.
EB Biobank ā Patient samples as resource for research
The targeted development of new treatments is not possible without suitable research material. That is why the EB RI operates the EB Biobank. Biological samples (e.g. blood, skin tissue, blister fluid) and associated clinical data are systematically collected and processed in the biobank. These samples form a valuable basis for better understanding the disease, identifying new targets for treatments and accelerating the development of innovative therapies. Through detailed datasets, the biobank also provides insights into disease progression and supports the precise development of future research areas.
Diagnostics and innovative methods
In addition to therapeutic research, the EB RI is working on the further development of sensitive and non-invasive diagnostic methods to enable the early and reliable detection of important complications associated with EB, such as skin tumours. Innovative screening approaches help to better assess clinical risks and take early action.
Scientific publications and open collaboration
Scientific findings are regularly published in international journals and serve as a basis for further research. By this, the EB RI contributes to the global knowledge base on EB.
In addition, the EB RI offers external partners access to patient-relevant models and resources via the Open Innovation EB Platform, to support joint research and development projects and accelerating the discovery of new treatment options.
ACCOUNT FOR DONATIONS
We will be extremely grateful for your donation to the following account:
IBAN: AT02 2011 1800 8018 1100
BIC: GIBAATWWXXX
TAX BENEFITS
The donation made by you is tax-deductible pursuant to Ā§4a, no. 3/Ā§4 of the Austrian Income Tax Act as a special expenditure (private persons) or as a business expenditure (companies).
INTEGRITY & TRANSPARENCY
Trust through tested donation security thanks to strict quality standards, transparency and continuous monitoring.